We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urinary Biomarker Found for Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 Nov 2010
A protein in urine could be a reliable marker for prostate cancer assessment and has advantages over the standard prostate specific antigen (PSA) test. More...


The protein, microseminoprotein-beta (MSMB), which is produced by normal prostate cells and secreted into urine from semen, regulates cell apoptosis or programmed cell death and is linked to an increased risk of developing prostate cancer.

In a multi-institute collaborative study, led by scientists from the Institute of Cancer Research, (CRUK; Cambridge, UK), tissue, urine and blood samples were analyzed from cohorts of prostate cancer patients. Urinary PSA and MSMB levels were determined by enzyme-linked immunoassays (ELISA) and normalized to creatinine. Samples from 133 of the patients were made into a tissue microarrays (TMA) containing multiple cores from normal/benign regions (>3), prostatic intraepithelial neoplasia (PIN) and at least two distinct regions of tumor for each patient. Genotyping was performed on DNA extracted from blood samples.

The urinary levels of MSMB were determined in 215 men with no history of prostate disease and 89 men with prostate cancer. Consistent with the association in prostate tissue there was a significant decrease in urinary MSMB in men with tumors compared with men with no history of prostate disease. No normal or tumorigenic tissues demonstrated any MSMB staining suggesting that at the protein level in tissue MSMB is highly prostate specific. In particular the tissues surrounding the prostate, such as urothelium, seminal vesicles and bladder muscularis propria layer showed no staining whereas adjacent benign prostate glands were heavily stained. MSMB demonstrated high levels of specificity and sensitivity particularly when compared to urinary PSA. There was a significant decrease in urinary MSMB with the high risk allele compared to the low risk allele.

Hayley Whitaker, Ph.D., the lead author, said, "Microseminoprotein-beta (MSMB), is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk". The study was published on line on October 13, 2010, in the open access journal from the Public Library of Science, PLoS One.

Related Links:
Institute of Cancer Research



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.